Technology Sectors & Industries

Therapeutics

Filter

Sectors

Industries

Clear all filters

anti-TCRVbeta Chimeric Antigen Receptors (CARs)

anti-TCRVbeta Chimeric Antigen Receptors (CARs)

anti-TCRVbeta Chimeric Antigen Receptors which can target pathological T cells in a highly selective manner, leaving >90% of the patient’s T cells and T cell-dependent immunity intact.

Treatment of Tissue Fibrosis

Treatment of Tissue Fibrosis

Itaconate and itaconate analogues capable of inhibiting succinate dehydrogenase can be used to treat or prevent tissue fibrosis.

Dr Britany Clarke

Dr Britany Clarke

Dr Britany Clarke is an Industry Partnership and Commercialisation Officer in the Faculty of Medicine at Imperial College London.

A novel targeted drug delivery system

A novel targeted drug delivery system

A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics

Edmond Yau

Edmond Yau

Edmond joined Imperial in February 2022 as an Industry Partnerships and Commercialisation Executive. He primarily takes care of IP and licensing cases from the Faculty of Natural Sciences. Prior to joining Imperial, Edmond worked in Royal College of Art as...

Dr Amritha Nair

Dr Amritha Nair

Dr Amritha Nair is an Industry Partnerships and Commercialisation Senior Executive in the Faculty of Medicine at Imperial College London. Amritha works across the entire innovation lifecycle from assessment, protection, and management of Intellectual property;...

Sign up for updates

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean nec venenatis arcu. In fermentum non tellus nec vulputate. Integer accumsan, nunc sit amet porta commodo, diam sapien feugiat purus, at imperdiet arcu nisi quis dui. Etiam vel nisl sem. Proin felis nisl, fringilla eu eros ac, sodales pellentesque sem.

Loading...